Bullisch
$8.18
Szenariopreis
$4.010
+0.199 (+4.97%)Zum Schluss
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.
P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

P3 Health Partners Appoints New Chief Clinical Officer

P3 Health Partners Reports Revenue Growth and Profitability in Q2 2026

Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement

Multiple Companies Experience Significant Stock Price Gains

P3 Health Partners Reports Strong Q1 2026 Earnings and Raises Outlook
P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).
P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.
Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.